Key Takeaway: Nurix is advancing its portfolio aimed at developing therapies for cancer and autoimmune diseases. The company emphasizes the importance of translating scientific insights into effective treatments. Their focus includes a novel BRAF degrader that shows promise for treating solid tumors, particularly those resistant to existing inhibitors.
Price reaction · baseline $26.45 (2024-10-28 close) · hit pre-market · 2 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
-4.7%
Market Sentiment Analysis
POSITIVE FACTORS
Focus on developing breakthrough therapies for cancer and autoimmune diseases.
Advancement of a multi-modal portfolio of assets.
Commitment to translating scientific insights into practical treatments.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is the focus of Nurix's research?
Nurix focuses on developing breakthrough therapies for cancer and autoimmune diseases.
What type of drug is Nurix developing?
Nurix is developing a pan-mutant BRAF degrader for treating solid tumors.
What diseases are targeted by Nurix's therapies?
Nurix's therapies target cancer and autoimmune diseases.